In June of this year, Gilead delivered a notice of termination to Roche of the companies’ 1996 agreement relating to Tamiflu and the companies subsequently entered into arbitration. However, the companies have now resolved the dispute between themselves.
Under the terms of the amended agreement, Gilead and Roche will establish joint committees to oversee manufacturing, commercial and pandemic planning for the product. Gilead will also have the option to co-promote Tamiflu in specialized areas in the US. Gilead will not co-promote Tamiflu in 2006 and has not yet determined whether it will exercise its option for co-promotion in 2007 or beyond.
“We have ended our dispute with Roche in an effort to work together, with the utmost diligence, to address this global public health need,” said Dr John Martin, president and CEO, Gilead Sciences.